Universal Cells
Steven Kattman is a Senior Director with expertise in immune homeostasis and pluripotent stem cell differentiation. Steven has held leadership roles at various companies such as Universal Cells, Sana Biotechnology, Inc., and Fujifilm Cellular Dynamics. Steven has a strong background in developing cell therapies for heart failure and Type 1 Diabetes. Their extensive experience includes leading research teams in both academia and industry, with a focus on translating cell therapies from the lab to the clinic. Steven's educational background includes a Bachelor of Science degree from Colorado State University and a PhD in Immunology from the University of Colorado Anschutz Medical Campus.
Universal Cells
Universal Cells is a Seattle-based biotech developing, licensing and commercializing stem cell therapies that overcome immune rejection and can be used to create true off-the-shelf therapeutic products. Using the company's proprietary genome editing approach, the company engineers stem cells to prevent expression of polymorphic human leukocyteantigen (HLA) molecules, removing the cause of donor tissue rejection and creating Universal Donor Stem Cells that are compatible with every patient.